ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Most CML patients will experience long term responses with tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogene and can in many cases be considered functionally cured of their disease (9, 11).